Lexicon Pharmaceuticals Reports 2007 Third Quarter Financi... ( Live Conference Call and Web...)

Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results

Date:10/30/2007

Live Conference Call and Webcast at 5:00 p.m. Eastern Time

THE WOODLANDS, Texas, Oct. 30 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today reported financial results for the three and nine months ended September 30, 2007.

"We continued to make progress in our 10to10 initiative in the third quarter, completing the Phase 1b clinical trial of LX1031, our drug candidate for the treatment of irritable bowel syndrome," said Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer. "The studies demonstrated that LX1031 was well-tolerated at all dose levels and we look forward to advancing it into Phase 2 clinical trials in 2008."

Highlights of the Third Quarter

-- Lexicon scientists presented data revealing the target of a new class

of internally-developed compounds that includes LX1031 and other

compounds under evaluation by the company as potential treatments for

irritable bowel syndrome (IBS) and other gastrointestinal disorders.

The compounds inhibit tryptophan hydroxylase 1 (TPH1), the key enzyme

responsible for producing serotonin in the gastrointestinal tract. In

preclinical studies with these molecules, serotonin levels could be

reduced in the intestine without affecting levels of the

neurotransmitter in the brain, where it mediates mood and other

behaviors.

-- Lexicon received stockholder approval for and completed a financing